Apimeds Pharmaceuticals US (APUS) Invested Capital (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Invested Capital for 4 consecutive years, with $120.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital changed N/A year-over-year to $120.4 million; the trailing twelve-month figure through Jun 2026 stood at $120.4 million (changed N/A YoY), and the FY2025 full-year result was $160.4 million, up 14578.48% from the prior year.
• Invested Capital eased to $120.4 million in Q2 2026 per APUS's latest filing, from $160.4 million in the prior quarter.
• Across five years, Invested Capital topped out at $160.4 million in Q4 2025 and bottomed at -$1.1 million in Q1 2025.
• Historically, Invested Capital has averaged $55.8 million across 4 years, with a median of $298760.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Invested Capital slumped 470.91% in 2024, then surged 14578.48% in 2025.
• Over 4 years, Invested Capital stood at $298760.0 in 2023, then plunged by 470.91% to -$1.1 million in 2024, then soared by 14578.48% to $160.4 million in 2025, then dropped by 24.98% to $120.4 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $120.4 million, $160.4 million, and -$1.1 million for Q2 2026, Q4 2025, and Q1 2025 respectively.